TNF and inflammatory bowel disease: Pharmacological treatment for IBD has progressed from a conventional treatment with low-selectivity aminosalicylates, immunosuppressants and corticosteroids, to a new generation of biopharmaceuticals, primarily monoclonal antibodies (mAb) targeting TNF-α, mainly in moderate to severe disease-resistant manifestations to conventional therapies.